The lower part expenditures is because, Conner, what happens when patients can afford their drugs, they stay on their drugs, theyre more compliant with their medicines, and they end up having healthier lives and not ending up in the emergency room or hospitalizations, which is significantly higher in expenditures
A cost-effectiveness analysis confirmed semaglutide provides significantly better value per unit of weight loss (Goulooze et al., 2023)
Tirzepatide slows the rate at which food and liquids leave the stomach, which under normal circumstances contributes to satiety and improved glucose control
Analysts project the market could expand fivefold within five years
This increase is not considered to be clinically significant
Distributor-level leakages and "cosmetic use" already being flagged before a single generic has hit the shelf